You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Monoclonal Antibody Treatment

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)

Not yet recruiting
  • Rectal Cancer
  • Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
  • (no location specified)
Aug 29, 2023

Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)

Not yet recruiting
  • Antibody-mediated Rejection
  • Kidney Tranplant
  • Hangzhou, Zhejiang, China
    79# Qingchun Road
Jun 21, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Assess New Participant's Perspectives Beyond Clinical Efficacy

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
    • (no location specified)
    Nov 7, 2023

    Advanced Solid Tumor Trial in Bengbu (HB0030 injection)

    Recruiting
    • Advanced Solid Tumor
    • HB0030 injection
    • Bengbu, Anhui, China
      the First Affiliated Hospital of Bengbu Medical College
    Jan 20, 2023

    Atopic Dermatitis Trial in Shanghai (MG-K10/Placebo)

    Active, not recruiting
    • Atopic Dermatitis
    • MG-K10/Placebo
    • Shanghai, China
      Huashan Hospital Affiliated to Fudan University
    Aug 31, 2023

    Acquired Hemophilia Trial in Tianjin (Daratumumab)

    Recruiting
    • Acquired Hemophilia
    • Tianjin, China
      Chinese Academy of Medical Science and Blood Disease Hospital
    May 5, 2023

    MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

    Not yet recruiting
    • MSS
    • Rectal Cancer
    • Sintilimab with Interleukin-2
    • (no location specified)
    Nov 1, 2023

    HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

    Completed
    Has Results
    • HER2 Positive Breast Carcinoma
    • +6 more
    • Palo Alto, California
      Stanford University, School of Medicine
    Sep 22, 2022

    Diabetic Polyneuropathy Trial in Rochester, Aarhus, Copenhagen (Eptinezumab, Placebo)

    Not yet recruiting
    • Diabetic Polyneuropathy
    • Rochester, Minnesota
    • +2 more
    Jun 30, 2023

    Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),

    Recruiting
    • Acute Gout
    • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
    • +6 more
    • Wuhan, Hubei, China
    • +2 more
    Oct 17, 2022

    Lymphoma, Non-Hodgkin, Lymphoma, T-Cell Trial in Najing (Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Lymphoma, T-Cell
    • Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
    • Najing, Jiangsu, China
      Jiangsu Provincial People's Hospital
    Sep 26, 2022

    Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

    Recruiting
    • Peripheral T-Cell Lymphoma, Not Otherwise Specified
    • Angioimmunoblastic T-cell Lymphoma
    • Changchun, Jilin, China
      The First Bethune Hospital of Jilin University
    Apr 7, 2023

    Ovarian Cancer Trial in New York (90Y-hu3S193, 111In-hu3S193)

    Completed
    Has Results
    • Ovarian Cancer
    • 90Y-hu3S193
    • 111In-hu3S193
    • New York, New York
      Memorial Sloan-Kettering Cancer Center
    Oct 3, 2022

    Ovarian Cancer Trial in New York (Monoclonal antibody hu3S193)

    Terminated
    Has Results
    • Ovarian Cancer
    • Monoclonal antibody hu3S193
    • New York, New York
      Memorial Sloan-Kettering Cancer Center
    Oct 3, 2022

    Healthy Trial in Qingdao (VDJ001, Placebo)

    Completed
    • Healthy
    • Qingdao, Shandong, China
      the Affliated Hospital of Qingdao University
    Aug 30, 2023

    Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

    Not yet recruiting
    • Colorectal Cancer
    • Hangzhou, Zhejiang, China
      Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
    Jan 30, 2023

    Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)

    Recruiting
    • Safety and Efficacy
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Sep 27, 2023

    Psoriasis Trial in Shanghai, Kunming (Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection, Placebo)

    Active, not recruiting
    • Psoriasis
    • Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
    • Placebo
    • Shanghai, Shanghai, China
    • +2 more
    Nov 7, 2022

    COVID-19 Trial in Joondalup (VYD222, Placebo)

    Recruiting
    • COVID-19
    • Joondalup, Western Australia, Australia
      Linear Clinical Research
    Apr 3, 2023

    Pyoderma, Pyoderma Gangrenosum, Pyoderma Vegetans Trial in Minsk, Riga (Monoclonal antibody (Mab) sB24M)

    Active, not recruiting
    • Pyoderma
    • +3 more
    • Monoclonal antibody (Mab) sB24M
    • Minsk, Belarus
    • +1 more
    Jul 8, 2022

    Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular

    Completed
    • AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
    • Wenzhou, Zhejiang, China
      The First Affiliated Hospital of Wenzhou Medical University
    Nov 6, 2023

    Lymphoma Trial (BYON4228 + Rituximab)

    Not yet recruiting
    • Lymphoma
    • BYON4228 + Rituximab
    • (no location specified)
    Feb 20, 2023